The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1253
ISSUE1253
January 29, 2007
Telbivudine (Tyzeka) for Chronic Hepatitis B
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Telbivudine (Tyzeka) for Chronic Hepatitis B
January 29, 2007 (Issue: 1253)
The FDA has approved the nucleoside analog telbivudine (Tyzeka - Novartis/Idenix) for treatment of patients ≥16 years old with active chronic hepatitis B virus (HBV) infection. It is the fourth oral drug marketed for this indication in the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.